Evidence map›Paper›PMID 31406393›Full record

ArticleProceedings of SPIE--the International Society for Optical Engineering2018

In vivo imaging of radiopaque resorbable inferior vena cava filter infused with gold nanoparticles.

Li Tian, Patrick Lee, Burapol Singhana, Aaron Chen, Yang Qiao, Linfeng Lu, Jonathan Martinez, Ennio Tasciotti, Megan C Jacobsen, Adam Melancon and 4 more

Abstract read
In one paragraph

Article in Proceedings of SPIE--the International Society for Optical Engineering, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Li TianDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Patrick LeeCollege of Medicine, State University of New York Upstate Medical University, Syracuse, NY 13210, USA.
Burapol SinghanaDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Aaron ChenMedical School, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
Yang QiaoDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Linfeng LuDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jonathan MartinezCenter for Biomimetic Medicine, Houston Methodist, Houston, TX 77030, USA.
Ennio TasciottiCenter for Biomimetic Medicine, Houston Methodist, Houston, TX 77030, USA.
Megan C JacobsenDepartment of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Adam MelanconDepartment of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Mark McArthurDepartment of Veterinary Medicine The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Mitch EggersAdient Medical, Pearland, TX 77584, USA.
Steve HuangDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Marites P MelanconDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
The University of Texas MD Anderson Cancer Center · USHouston Methodist · USAdient Medical (United States) · USSUNY Upstate Medical University · USThe University of Texas Health Science Center at Houston · US

Funding

Nanoparticle- Infused Radiopaque Absorbable Medical DeviceR01HL141831 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MELANCON, MARITES PASUELO · 2018 to 2022
$1.9M
Nanoparticle-Infused Radiopaque Absorbable Medical DeviceR56HL131633 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MELANCON, MARITES PASUELO · 2016 to 2016
$405k
NHLBI NIH HHS R01 HL141831NHLBI NIH HHS R56 HL131633
6 · The paper itself

Abstract

Radiopaque resorbable inferior vena cava filter (IVCF) were developed to offer a less expensive alternative to assessing filter integrity in preventing pulmonary embolism for the recommended prophylactic period and then simply vanishes without intervention. In this study, we determined the efficacy of gold nanoparticle (AuNP)-infused poly-p-dioxanone (PPDO) as an IVCF in a swine model. Infusion into PPDO loaded 1.14±0.08 % AuNP by weight as determined by elemental analysis. The infusion did not alter PPDO's mechanical strength nor crystallinity (Kruskal-Wallis one-way ANOVA, p<0.05). There was no cytotoxicity observed (one-way ANOVA, p<0.05) when tested against RF24 and MRC5 cells. Gold content in PPDO was maintained at ~2000 ppm during the 6-week incubation in PBS at 37°C. As a proof-of-concept, two pigs were deployed with IVCF, one with AuNP-PPDO and the other without coating. Results show that the stent ring of AuNP-PPDO was highly visible even in the presence of iodine-based contrast agent and after clot introduction, but not of the uncoated IVCF. Autopsy at two weeks post-implantation showed AuNP-PPDO filter was endothelialized onto the IVC wall, and no sign of filter migration was observed. The induced clot was also still trapped within the AuNP-PPDO IVCF. As a conclusion, we successfully fabricated AuNP-infused PPDO IVCF that is radiopaque, has robust mechanical strength, biocompatible, and can be imaged effectively in vivo. This suggests the efficacy of this novel, radiopaque, absorbable IVCF for monitoring its position and integrity over time, thus increasing the safety and efficacy of deep vein thrombosis treatment.

Indexed as

Gold nanoparticles (AuNP)inferior vena cava filter (IVCF)poly-p-dioxanone (PPDO)pulmonary embolismx-ray and computed tomography (CT)

Identifiers

PMID31406393
PMCPMC6690051
OpenAlexW2791697321

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.